PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Form 10-Q — May 14, 2026
Provectus Biopharmaceuticals reported a net loss of $1.3 million for the first quarter of 2026, driven by $1.25 million in operating expenses and zero revenue. The company holds only $223,883 in cash against a working capital deficit of $6.78 million and an accumulated deficit of $264 million. Management explicitly stated that these conditions raise 'substantial doubt about the Company’s ability to continue as a going concern' within one year. The company is actively raising capital through its 2025 Financing program, having secured $335,000 in new convertible note proceeds during the quarter, but faces significant liquidity risk if it cannot secure additional funding.
Key figures
- Revenue
- 0
- Cash Position
- 223883
- Ga Expenses
- 914569
- Rd Expenses
- 333334
- Shares Outstanding
- 420279879
- Convertible Notes Outstanding
- 2390000
- Interest Rate Convertible Notes
- 8%
Price after filing
Close on the filing date to close N calendar days later (from $0.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.